Source:http://linkedlifedata.com/resource/pubmed/id/17047046
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
20
|
| pubmed:dateCreated |
2006-10-18
|
| pubmed:abstractText |
Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma. The deletions usually involve whole chromosome arms, suggesting a t(1;19)(q10;p10). Using stem cell medium, we cultured a few tumors. Paraffin-embedded tissue was obtained from 21 Mayo Clinic patients and 98 patients enrolled in 2 North Central Cancer Treatment Group (NCCTG) low-grade glioma trials. Interphase fusion of CEP1 and 19p12 probes detected the t(1;19). 1p/19q deletions were evaluated by fluorescence in situ hybridization. Upon culture, one oligodendroglioma contained an unbalanced 45,XX,t(1;19)(q10;p10). CEP1/19p12 fusion was observed in all metaphases and 74% of interphase nuclei. Among Mayo Clinic oligodendrogliomas, the prevalence of fusion was 81%. Among NCCTG patients, CEP1/19p12 fusion prevalence was 55%, 47%, and 0% among the oligodendrogliomas, mixed oligoastrocytomas, and astrocytomas, respectively. Ninety-one percent of NCCTG gliomas with 1p/19q deletion and 12% without 1p/19q deletion had CEP1/19p12 fusion (P < 0.001, chi(2) test). The median overall survival (OS) for all patients was 8.1 years without fusion and 11.9 years with fusion (P = 0.003). The median OS for patients with low-grade oligodendroglioma was 9.1 years without fusion and 13.0 years with fusion (P = 0.01). Similar significant median OS differences were observed for patients with combined 1p/19q deletions. The absence of alterations was associated with a significantly shorter OS for patients who received higher doses of radiotherapy. Our results strongly suggest that a t(1;19)(q10;p10) mediates the combined 1p/19q deletion in human gliomas. Like combined 1p/19q deletion, the 1;19 translocation is associated with superior OS and progression-free survival in low-grade glioma patients.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0008-5472
|
| pubmed:author |
pubmed-author:ArusellRobert MRM,
pubmed-author:BallmanKarla VKV,
pubmed-author:BlairHilaryH,
pubmed-author:BrownPaul DPD,
pubmed-author:BucknerJan CJC,
pubmed-author:FeltenSaraS,
pubmed-author:FlynnHeatherH,
pubmed-author:GianniniCaterinaC,
pubmed-author:JenkinsRobert BRB,
pubmed-author:LawMarkM,
pubmed-author:PasseSandraS,
pubmed-author:ShawEdward GEG
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
66
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
9852-61
|
| pubmed:dateRevised |
2011-10-13
|
| pubmed:meshHeading |
pubmed-meshheading:17047046-Adolescent,
pubmed-meshheading:17047046-Adult,
pubmed-meshheading:17047046-Aged,
pubmed-meshheading:17047046-Cell Cycle Proteins,
pubmed-meshheading:17047046-Chromosome Deletion,
pubmed-meshheading:17047046-Chromosomes, Human, Pair 1,
pubmed-meshheading:17047046-Chromosomes, Human, Pair 12,
pubmed-meshheading:17047046-Clinical Trials, Phase II as Topic,
pubmed-meshheading:17047046-Clinical Trials, Phase III as Topic,
pubmed-meshheading:17047046-Female,
pubmed-meshheading:17047046-Humans,
pubmed-meshheading:17047046-Interphase,
pubmed-meshheading:17047046-Male,
pubmed-meshheading:17047046-Middle Aged,
pubmed-meshheading:17047046-Multivariate Analysis,
pubmed-meshheading:17047046-Oligodendroglioma,
pubmed-meshheading:17047046-Prognosis,
pubmed-meshheading:17047046-Translocation, Genetic
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
|
| pubmed:affiliation |
Mayo Clinic, Rochester, Minnesota 55905, USA. rjenkins@mayo.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|